← Back to Search

Lenalidomide for Lymphoma

Phase 1 & 2

Waitlist Available

Led By Jakub Svoboda, MD

Research Sponsored by Abramson Cancer Center of the University of Pennsylvania

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 12 months from start of lenalidomide maintenance

Awards & highlights

Study Summary

This trial is testing the safety and effectiveness of the drug lenalidomide in preventing lymphoma from returning after stem cell transplant. If successful, it could be approved for use in the US.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 12 months from start of lenalidomide maintenance

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~12 months from start of lenalidomide maintenance

This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months from start of lenalidomide maintenance for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Number of Subjects With Dose-limiting Toxicities

Secondary outcome measures

Overall Survival

Progression Free Survival

Trial Design

1Treatment groups

Experimental Treatment

Group I: Phase I/II (Maintenance Lenalidomide in Lymphoma)Experimental Treatment1 Intervention

Total of 24 cycles of lenalidomide. Subjects received a starting daily dose of 10mg lenalidomide on days 1 through 28 of each 28 day cycle. Subjects initiated lenalidomide 28-100 days post-ASCT.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Lenalidomide

2005

Completed Phase 3

~1480

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Abramson Cancer Center of the University of PennsylvaniaLead Sponsor

359 Previous Clinical Trials

105,087 Total Patients Enrolled

14 Trials studying Lymphoma

396 Patients Enrolled for Lymphoma

Abramson Cancer Center at Penn MedicineLead Sponsor

387 Previous Clinical Trials

145,687 Total Patients Enrolled

15 Trials studying Lymphoma

405 Patients Enrolled for Lymphoma

Jakub Svoboda, MDPrincipal InvestigatorAbramson Cancer Center at Penn Medicine

6 Previous Clinical Trials

164 Total Patients Enrolled

4 Trials studying Lymphoma

68 Patients Enrolled for Lymphoma

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the aggregate count of participants enrolled in this clinical trial?

"At this time, recruitment for this trial has been concluded. First posted on April 1st 2012 and most recently amended June 3rd 2022, it is no longer enrolling patients. However, there are still 1717 clinical trials searching for lymphoma participants and 267 studies involving Lenalidomide which remain open to applicants."

Answered by AI

Is enrollment for this trial currently open?

"This clinical trial is not recruiting participants currently, as indicated on the data hosted on clinicaltrials.gov for this study which was first released April 1st 2012 and most recently updated June 3rd 2022. However, there are1984 other trials actively seeking out candidates across the world at this time."

Answered by AI

What are the common applications of Lenalidomide?

"Lenalidomide is a commonly prescribed drug for multiple myeloma. Additionally, it has been known to help patients with refractory lymphomas, chronic lymphocytic leukemia and those who have already received two courses of chemotherapy."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Maintenance Lenalidomide in Lymphoma

2012. "Maintenance Lenalidomide in Lymphoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01575860.